Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA Firms Up February 2025 Date For Shortages Monitoring Platform

Plans To Integrate ESMP With Other Data Sources

Executive Summary

During the recent Medicines for Europe 2022 annual conference, held in Sitges, Barcelona, the EMA’s head of supply and availability of medicines and devices, Monica Dias, provided delegates with a detailed update on plans to implement the agency’s major shortages monitoring platform by early 2025.

You may also be interested in...



Generics Bulletin Editor’s Picks For Q2 2022

Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.

New EU Bodies To Monitor Drug Supply In Health Crises

New pandemic-related responsibilities have been entrusted to the European Medicines Agency by a regulation published on 31 January. They include coordinating vaccine safety and effectiveness studies and setting up a European network of real-world data to help support health crisis preparedness and response.

Biocon Meets $650m Equity Infusion In Biocon Biologics To Fund Viatris Buy

Biocon Biologics is continuing to rack up the capital needed to close its multi-billion deal for Viatris’ global biosimilars business, with two quick equity investments from parent Biocon Limited as stipulated under its acquisition agreement.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB152005

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel